UK markets closed

NLS Pharmaceutics Ltd. (NLSP)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
0.1367+0.0043 (+3.25%)
At close: 04:00PM EDT
0.1368 +0.00 (+0.07%)
After hours: 04:22PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 5.92M
Enterprise value 4.92M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)4.84
Enterprise value/revenue N/A
Enterprise value/EBITDA -0.32

Trading information

Stock price history

Beta (5Y monthly) -0.84
52-week change 3-89.30%
S&P500 52-week change 322.36%
52-week high 31.5300
52-week low 30.1130
50-day moving average 30.2509
200-day moving average 30.5650

Share statistics

Avg vol (3-month) 3587.38k
Avg vol (10-day) 3227.24k
Shares outstanding 543.32M
Implied shares outstanding 643.32M
Float 819.89M
% held by insiders 131.54%
% held by institutions 123.84%
Shares short (15 Apr 2024) 475.11k
Short ratio (15 Apr 2024) 40.05
Short % of float (15 Apr 2024) 40.23%
Short % of shares outstanding (15 Apr 2024) 40.17%
Shares short (prior month 15 Mar 2024) 435.24k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2022
Most-recent quarter (mrq)30 Jun 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-414.25%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -14.33M
Net income avi to common (ttm)-15.47M
Diluted EPS (ttm)-0.5000
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)1.65M
Total cash per share (mrq)0.05
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)0.58
Book value per share (mrq)-0.13

Cash flow statement

Operating cash flow (ttm)-13.51M
Levered free cash flow (ttm)-7.95M